[HTML][HTML] Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis
D Planchard, B Besse, HJM Groen… - Journal of Thoracic …, 2022 - Elsevier
Introduction Dabrafenib plus trametinib was found to have robust antitumor activity in
patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated …
patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated …
Spruce giga‐genomes: structurally similar yet distinctive with differentially expanding gene families and rapidly evolving genes
Spruces (Picea spp.) are coniferous trees widespread in boreal and mountainous forests of
the northern hemisphere, with large economic significance and enormous contributions to …
the northern hemisphere, with large economic significance and enormous contributions to …
[HTML][HTML] Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care
Genomic research is driving discovery for future population benefit. Limited evidence exists
on immediate patient and health system impacts of research participation. This study uses …
on immediate patient and health system impacts of research participation. This study uses …
[PDF][PDF] Genomic sequencing to guide cancer management
J Oristaglio, M Manso-Share, P Madireddi, B Wilkinson… - 2021 - ecwebmaster.com
Genomic testing is a critical component of precision medicine. It has influenced many
aspects of patient care, including diagnosis, disease monitoring, and treatment choice …
aspects of patient care, including diagnosis, disease monitoring, and treatment choice …
[HTML][HTML] Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC Folgen
NEL ASA, A SE - markets.ft.com
Tabrecta is the first therapy approved by the FDA to specifically target metastatic non-small
cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping …
cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping …
[HTML][HTML] Ulkoasun asetukset Uutta
KL Nyt, KL Oma - Hypertension (high blood pressure) - kauppalehti.fi
Basel, March 24, 2020–AveXis, a Novartis company, today announced a one-time infusion
of Zolgensma®(onasemnogene abeparvovec-xioi) showed rapid, significant and clinically …
of Zolgensma®(onasemnogene abeparvovec-xioi) showed rapid, significant and clinically …